KLRS — Kalaris Therapeutics Balance Sheet
0.000.00%
- $49.00m
- -$51.96m
Annual balance sheet for Kalaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 356 | 248 | 234 | 184 | 118 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.45 | 0.05 | 0.157 | 0.206 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 361 | 253 | 243 | 188 | 119 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.5 | 31.3 | 32.6 | 2.19 | — |
Other Long Term Assets | |||||
Total Assets | 371 | 287 | 277 | 191 | 119 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12.3 | 37.9 | 24.3 | 28.4 | 5.24 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 17.8 | 61.3 | 52.6 | 45 | 5.24 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 353 | 225 | 225 | 146 | 113 |
Total Liabilities & Shareholders' Equity | 371 | 287 | 277 | 191 | 119 |
Total Common Shares Outstanding |